Boston, MA -- (SBWire) -- 08/16/2013 --Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. The disease has emerged as a major global health priority especially because of its rapidly accelerating prevalence worldwide. In order to tackle the AD scourge , there is an urgent need for tools that will allow for the early and accurate diagnosis of AD, as well as the identification of populations at risk. A biomarker is an indicator of biological processes that can be objectively measured and evaluated, and well-validated biomarkers are required to satisfy these needs in AD.
The search for biomarkers that are reflective of the disease process in AD has been and continues to be an active area of research, but has been hampered by a lack of clear understanding of the pathological mechanisms that underlie the disease. Nonetheless, several biomarkers have been developed to date that indicate the presence of AD pathology and AD-associated neuronal injury in vivo. Such biomarkers have the potential for clinical use in etiological determination, predictive prognosis, monitoring disease progression, and in clinical trials of potential disease-modifying therapies for AD.
View Full Report Details and Table of Contents
Highlights
Key Questions Answered
- What are the main biomarkers in AD? What AD biomarkers are commercially available in the market and which are in pipeline development?
- What are the roles of biomarkers in AD diagnosis and drug discovery?
- What are the major unmet needs with regards to AD biomarkers?
- What are the views of KOLs on the present and future landscape of the AD biomarkers market?
- What is the impact of government regulation on AD biomarker development and market adoption? What governmental and industry changes are likely to influence the use of biomarkers in the near future?
Key Findings
- Amyloid-based biomarkers, and in particular, amyloid PET ligands, are the furthest developed biomarkers for AD and although they have immense value in diagnosis and drug discovery, there is a remaining need for biomarkers of other pathological processes.
- There is a great need for simple inexpensive biomarker assays that can be implement as diagnostic screens for AD and there are numerous blood-based biomarker assays in pipeline aiming to target this need.
- Government regulation will play a major role in biomarker development, clinical market access and use in drug discovery both in the US and in the EU.
Scope
- Overview of Alzheimer's disease, including disease etiology and pathophysiology and how these inform biomarker targets.
- Overview of AD biomarkers, the major classes of biomarkers an the different potential roles of biomarkers in clinical use and drug development.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
- PharmaFocus: Vaccine Adjuvants in Infectious Disease
- Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson's disease treatment will boost market despite patent cliff
- Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Global Clinical Trials Review, H2, 2012
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2013
- Alzheimer's Disease Global Clinical Trials Review, H2, 2012
- Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2012
- Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012
- Coronary Disease Global Clinical Trials Review, H1, 2013
- Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2012
Market Report, "PharmaFocus: Biomarkers in Alzheimer's Disease", Published
New Pharmaceuticals research report from GlobalData is now available from Fast Market Research